Donna Reece

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Anthony Boral, Hartmut Goldschmidt, Mario Boccadoro, 2007, Blood.

CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

S. Jagannath, G. Gahrton, D. Reece, 1998, British journal of haematology.

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

Jessica Katz, Hermann Einsele, Paul Richardson, 2015, The New England journal of medicine.

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Hartmut Goldschmidt, Mario Boccadoro, David Irwin, 2005, The New England journal of medicine.

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

Hong Chang, S. Trudel, M. Wiesmann, 2004, Blood.